Loading stock data…
$39.62-0.90 (-2.22%)
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases.
Scholar Rock Holding Corporation in the Healthcare sector is trading at $39.62 with a market capitalization of $5.1B. Wall Street consensus targets $70.44 (16 analysts), implying a +77.8% move over the next 12 months. The stock is currently 36% below its 52-week high of $61.76, remaining 18.0% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 14 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$108.90M↓ | -$102.02M↓ | -$91.90M↑ | -$103.55M↑ | -$112.11M |
| Net Income | -$109.90M↓ | -$105.51M↓ | -$90.97M↑ | -$102.22M↑ | -$110.03M |
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding...